This activity was originally broadcast live as a satellite symposium held in conjunction with HOPA 2023.
Program Description
BCR-ABL1-targeted tyrosine kinase inhibitors (TKIs) allow most patients with chronic myeloid leukemia (CML) to maintain durable responses, however, these agents are associated with a unique set of challenges, including the toxicities, drug interactions, development of resistance, and treatment nonadherence. This program will review clinical data supporting use of second- and third-generation BCR-ABL1-targeting TKIs for the treatment of relapsed/refractory CML. Panelists will review guideline-recommended strategies for selection of these agents based on patient- and disease-specific characteristics. Considerations for managing TKI therapy for patients with CML who experience inadequate response, resistance, or TKI-related toxicities will also be presented.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: April 14, 2023
Expiration date: April 14, 2024
Time to complete activity: 1.0 hour
Learner level: Advanced
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Examine new and emerging data in chronic myeloid leukemia (CML) and its application to clinical practice
- Identify when switching to alternate tyrosine kinase inhibitor (TKI) therapy is warranted in patients with inadequate response
- Determine the most common toxicities associated with TKI therapy in patients with CML and strategies for their management
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
